ReviewSeminars in cancer biology2007
Mobilizing the low-avidity T cell repertoire to kill tumors.
Review in Seminars in cancer biology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Article
- The landscape of T cell antigens for cancer immunotherapy.Nature cancer · 2023Review
- A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy.Journal of experimental & clinical cancer research : CR · 2023Article
- Extracellular Vesicles in Lung Cancer: Prospects for Diagnostic and Therapeutic Applications.Cancers · 2021Review
- Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor.Journal for immunotherapy of cancer · 2021Article
- The armed oncolytic adenovirus ZD55-IL-24 eradicates melanoma by turning the tumor cells from the self-state into the nonself-state besides direct killing.Cell death & disease · 2020Article
- Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses.Frontiers in immunology · 2020Article
- Low Avidity T Cells Do Not Hinder High Avidity T Cell Responses Against Melanoma.Frontiers in immunology · 2019Article
- The Antitumor Effects of Vaccine-Activated CD8Cancer immunology research · 2017Article
- Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells.Oncotarget · 2016Article
- A generalized framework for computational design and mutational scanning of T-cell receptor binding interfaces.Protein engineering, design & selection : PEDS · 2016Article
- CD4+ T Cell Help Selectively Enhances High-Avidity Tumor Antigen-Specific CD8+ T Cells.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Enhancing Human Immunodeficiency Virus-Specific CD8(+) T Cell Responses with Heteroclitic Peptides.Frontiers in immunology · 2015Review
- Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens.Frontiers in immunology · 2015Review
- Amino acids and immune response: a role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer?Pathology oncology research : POR · 2015Review
- Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.European journal of immunology · 2014Article
- Article
- Molecular insights for optimizing T cell receptor specificity against cancer.Frontiers in immunology · 2013Article
- Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens.Cancer research · 2013Article
- Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection.The Journal of experimental medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Optimally, T cells destroy infected and transformed cells of the host. To be effective the T cell repertoire must have a sufficiently diverse number of T cell receptors (TCRs) to recognize the abundance of foreign and tumor antigens presented by MHC molecules. The T cell repertoire must also not be reactive toward self-antigens on healthy cells to prevent autoimmunity. Unlike antigens derived from pathogens, most tumor-associated antigens (TAA) are also self-antigens. Therefore, central and peripheral tolerance mechanisms delete or inhibit tumor-reactive T cells. Although there are T cells within the peripheral repertoire that recognize TAA, these T cells are not sufficient to prevent growth of clinically relevant tumors. We will discuss how this dysfunction results, in part, from the low functional avidity of T cells for tumor, or antigen presenting cells (APC) displaying TAA. We discuss the limitations of these low-avidity tumor-reactive T cells and review current immunotherapies aimed at enhancing the avidity and antitumor activity of the tumor-specific T cell repertoire.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.